智通财经APP获悉，香港联交所最新资料显示，12月30日，小摩增持康龙化成(03759)145.6225万股，每 股作价19.388港元，总金额约为2823.33万港元。增持后最新持股数目约为1581.03万股，最新持股比例 为5.24%。 ...

香港联交所最新资料显示，12月30日，小摩增持康龙化成（300759）(03759)145.6225万股，每股作价 19.388港元，总金额约为2823.33万港元。增持后最新持股数目约为1581.03万股，最新持股比例为 5.24%。 ...

Group 1 - The CRO (Contract Research Organization) sector stocks are showing strong performance, with notable increases in share prices [1] - Zhaoyan New Drug (06127.HK) has risen by 11.52%, reaching HKD 22.26 [1] - Tigermed (03347.HK) has increased by 5.98%, now priced at HKD 44.98 [1] - WuXi AppTec (02359.HK) has gained 4.65%, with shares at HKD 105.7 [1] - Kanglong Chemical (03759.HK) has seen a rise of 4.59%, trading at HKD 20.74 [1]

Group 1 - CRO concept stocks are performing strongly, with notable increases in share prices: Zhaoyan New Drug up 11.52% to HKD 22.26, Tigermed up 5.98% to HKD 44.98, WuXi AppTec up 4.65% to HKD 105.7, and Kanglong Chemical up 4.59% to HKD 20.74 [1] - Huafu Securities reports that external demand for CXO companies has significantly improved since 2024, with a recovery in year-on-year growth expected from Q4 2024 through Q3 2025, indicating a clear trend of industry rebound [1] - Yongxing Securities notes that the domestic CXO industry is experiencing an upward trend in light of improved investment and financing conditions for innovative drugs, with strong demand for specialized CDMO services driven by the expanding market for emerging fields such as peptides, CGT, ADC, and nucleic acid drugs [1] Group 2 - The domestic CXO sector has shown relatively weaker performance compared to external demand since the beginning of 2025, but there is a strong certainty of recovery from the front-end to the back-end, suggesting potential left-side opportunities [1] - Chinese CDMO companies are expected to open growth ceilings through capacity expansion, technological layout, and model innovation, building barriers in niche markets while accommodating global orders [1]

Group 1 - The CRO sector is showing strong performance, with notable stock increases: Zhaoyan New Drug up 11.52% to HKD 22.26, Tigermed up 5.98% to HKD 44.98, WuXi AppTec up 4.65% to HKD 105.7, and Kanglong Chemical up 4.59% to HKD 20.74 [1] - Huafu Securities reports that external demand for CXO companies has significantly improved since 2024, with a recovery in year-on-year growth expected from Q4 2024 through Q3 2025, indicating a clear trend of industry rebound [1] - Yongxing Securities notes that the domestic CXO industry is experiencing an upward trend in light of improved investment and financing conditions for innovative drugs, with strong demand for specialized CDMO services driven by the expanding market for emerging fields such as peptides, CGT, ADC, and nucleic acid drugs [1] Group 2 - The domestic CXO sector has shown relatively weaker performance compared to external demand since the beginning of 2025, but there is a strong certainty of recovery from the front-end to the back-end, suggesting potential left-side opportunities [1] - Chinese CDMO companies are expected to open growth ceilings through capacity expansion, technological layout, and model innovation, building barriers in niche areas while accommodating global orders [1]

截至发稿，昭衍新药(06127.HK)涨9.72%、泰格医药(03347.HK)涨5.94%、康龙化成(03759.HK)涨 3.68%。 本文源自：金融界AI电报 ...

Group 1 - The Hong Kong stock market saw a decline in CRO (Contract Research Organization) concept stocks, with notable drops in several companies [1] - Zhaoyan New Drug fell over 7%, while Kanglong Chemical and King’s Ray dropped over 4% [1] - Kylin and Weiya Bio experienced declines of over 2% [1]

Group 1 - The company Kanglong Chemical announced that its actual controller, Lou Xiaoqiang, pledged 5,220,000 shares, accounting for 8.62% of his holdings [1] - The company's concerted action parties, Longtai Kang and Beihai Duotai, collectively released the pledge of 6,930,000 shares and extended the pledge of 15,970,000 shares until December 25, 2026 [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年12月24日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；職工 代表董事李承宗先生；非執行董事李家慶先生及萬璇女士；獨立非執行董事李麗 華女士、曾勁峰教授及余堅先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-071 关于公司实际控 ...

Group 1 - The core point of the news is that Kanglong Chemical conducted a block trade on December 24, with a transaction volume of 1.38 million shares and a transaction amount of 39.5363 million yuan, at a price of 28.65 yuan, which is a 0.90% discount compared to the closing price of the day [2][3] - In the last three months, Kanglong Chemical has recorded a total of 9 block trades, with a cumulative transaction amount of 266 million yuan [2] - The closing price of Kanglong Chemical on the day of the report was 28.91 yuan, reflecting a 0.35% increase, with a daily turnover rate of 0.95% and a total transaction amount of 391 million yuan, alongside a net inflow of main funds amounting to 6.1722 million yuan [2][3] Group 2 - The latest margin financing balance for Kanglong Chemical is 1.111 billion yuan, which has increased by 14.5693 million yuan over the past five days, representing a growth rate of 1.33% [3] - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, with a registered capital of 1.778195525 billion yuan [3]